Enliven Therapeutics (NASDAQ:ELVN) COO Sells $134,006.70 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of the business’s stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $20.10, for a total value of $134,006.70. Following the completion of the sale, the chief operating officer directly owned 276,641 shares in the company, valued at approximately $5,560,484.10. This represents a 2.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Anish Patel also recently made the following trade(s):

• On Monday, September 8th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.24, for a total value of $134,940.08.
• On Thursday, August 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.24, for a total value of $121,606.08.

Enliven Therapeutics Price Performance

Shares of ELVN stock opened at $20.82 on Friday. The stock’s fifty day simple moving average is $19.73 and its 200 day simple moving average is $19.56. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -10.41 and a beta of 0.85. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.04. On average, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ELVN shares. HC Wainwright boosted their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, July 2nd. The Goldman Sachs Group started coverage on Enliven Therapeutics in a research note on Monday, June 16th. They issued a “buy” rating and a $37.00 price objective on the stock. Robert W. Baird boosted their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, June 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Enliven Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $41.20.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Invesco Ltd. raised its position in shares of Enliven Therapeutics by 4.3% during the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after acquiring an additional 913 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after acquiring an additional 930 shares during the last quarter. Quantbot Technologies LP raised its position in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after acquiring an additional 1,434 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Enliven Therapeutics by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after acquiring an additional 1,693 shares during the last quarter. Finally, California State Teachers Retirement System increased its holdings in Enliven Therapeutics by 10.2% in the fourth quarter. California State Teachers Retirement System now owns 20,914 shares of the company’s stock valued at $471,000 after purchasing an additional 1,940 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.